- Clinical Professor, Global Health
HIV Prevention Research Unit
Medical Research Council
Select from the following:
Gita Ramjee PhD FRCPE is a Chief Specialist Scientist and Director of the South African Medical Research Council’s HIV Prevention Research Unit. She holds an Honorary Professorship from the London School of Hygiene and Tropical Medicine, London.
Dr Ramjee is world renowned, specializing in HIV prevention and treatment research with integrated care programmes among women and men in communities around the greater Durban area in South Africa. As the Clinical Trials Unit Principal Investigator, she has had oversight of an expansive portfolio of phase I through phase III HIV prevention and treatment clinical trials. She has been acknowledged internationally for her expertise in the field of microbicide research, including a Lifetime Achievement Award for HIV Prevention in 2012. Dr Ramjee has published more than 170 research articles. She is a reviewer and editor of several scientific journals and a member of several local and international committees and advisory groups including the Academy of Science of South Africa (ASSAf) and the South African National AIDS Council (SANAC).
Dr Ramjee has contributed substantially to advancing HIV prevention science among women in South Africa and is considered a critical player in the field of HIV prevention clinical trials.
- PhD (University of Natal)
- MSc (University of Natal)
- BSc (University of Sunderland)
- Infectious Diseases
- STDs (other than HIV)
- A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women (MTN 025/HOPE)
- HIV Risk Assessment Tool to Guide Interventions in "HIV Hotspots"
- HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in preventing HIV-1 infection in adults in South Africa
- HVTN 703/HPTN 081: A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
Baeten JM, Palanee‑Phillips T, Brown ER et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. NEJM DOI: 10.1056/NEJMoa1506110
Ramjee G, McCormack S. The role of progestins in HIV acquisition in young women. Lancet Infectious Diseases. DOI: http://dx.doi.org/10.1016/S1473-3099(15)00476-4
Handan Wand; Tarylee Reddy; Sarita Naidoo; Suri Moonsamy; Samantha Siva; Neetha Morar; Gita Ramjee. "A simple risk prediction algorithm for HIV transmission: results from HIV prevention trials conducted in KwaZulu Natal, South Africa (2002-2012)". AIDS and Behavior. https://link.springer.com/article/10.1007/s10461-017-1785-7
Ramjee G, Moonsamy S, Abbai NS, Wand H (2016) Individual and Population Level Impact of Key HIV Risk Factors on HIV Incidence Rates in Durban, South Africa. PLoS ONE 11(4): e0153969. doi:10.1371/journal.pone.0153969
Holly Janes, Lawrence Corey, Gita Ramjee, Lindsay N. Carpp, Myron S. Cohen, Peter B. Gilbert, and Glenda E. Gray. Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. AIDS Research and Human Retroviruses. DOI: 10.1089/aid.2018.0031